The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|13|4|411-422

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.13, Iss.4, 2013-05, pp. : 411-422

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL

By Yerbes Rosario  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 541-547

Springer Publishing Company

Access to resources Recommend Favorite

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer

By Acharya Milin   Karp Judith   Sausville Edward   Hwang Kyunghwa   Ryan Qin   Gojo Ivana   Venitz Jűrgen   Figg William   Sparreboom Alex  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 367-375

Springer Publishing Company

Access to resources Recommend Favorite

Intranasal gemcitabine eradicates osteosarcoma lung metastases

By  

Inpharma, Vol. 1, Iss. 1331, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells

By Oh Eun-Taex  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 435-442

Springer Publishing Company

Access to resources Recommend Favorite

Anti-Tumorigenic Effects of Resveratrol in Lung Cancer Cells Through Modulation of c-FLIP

By  

Current Cancer Drug Targets, Vol. 17, Iss. 7, 2017-08 ,pp. : 669-680

Bentham Science Publishers

Access to resources Recommend Favorite